Daclatasvir plus sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison

被引：6
|
作者：
Swallow, Elyse [1 ]
Song, Jinlin [1 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Kelley, Caroline [1 ]
Mu, Fan [1 ]
Kim, Soomi [1 ]
Noviello, Stephanie [2 ]
Signorovitch, James [1 ]
机构：
[1] Anal Grp Inc, 111 Huntington Ave,10th Floor, Boston, MA 02199 USA
[2] Bristol Myers Squibb Co, 100 Nassau Pk Blvd, Princeton, NJ 08540 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2016年 / 5卷 / 02期
关键词：
daclatasvir; hepatitis C genotype 3; matching-adjusted indirect comparison; peginterferon; ribavirin; sofosbuvir; SUSTAINED VIROLOGICAL RESPONSE; PEGINTERFERON ALPHA-2A; VIRUS; RIBAVIRIN; INFECTION;
D O I：
10.2217/cer.15.49
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3. Patients & methods: Clinical trials of SOF + R or A/R were identified in systematic literature reviews. The DCV+ SOF population was adjusted via propensity score weighting to match average baseline characteristics to those reported for the comparator regimens. Results: The SVR12 rate was similar between DCV + SOF and SOF + R, and significantly higher with DCV + SOF than A/R. Rates of discontinuation due to AEs were similar or significantly lower in patients treated with DCV + SOF than SOF + R or A/R. Conclusion: With its high efficacy and improved tolerability, DCV + SOF is an important treatment for hepatitis C genotype 3.
引用
收藏
页码：129 / 139
页数：11
相关论文
共 50 条
  • [1] COMPARATIVE EFFICACY AND TOLERABILITY OF DACLATASVIR plus SOFOSBUVIR VERSUS SOFOSBUVIR plus RIBAVIRIN FOR HEPATITIS C GENOTYPE 3: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Song, J.
    Yuan, Y.
    Kalsekar, A.
    Kelley, C.
    Mu, F.
    Kim, S.
    Noviello, S.
    Signorovitch, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S665 - S665
  • [2] DACLATASVIR plus ASUNAPREVIR VERSUS SOFOSBUVIR/LEDIPASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN JAPANESE PATIENTS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Kelley, C.
    Ristovska, L.
    Signorovitch, J. E.
    Kalsekar, A.
    Wygant, G.
    McPhee, F.
    VALUE IN HEALTH, 2015, 18 (07) : A576 - A576
  • [3] Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Ackerman, Peter
    Signorovitch, James
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 404 - 412
  • [4] Comparative Efficacy and Tolerability of Daclatasvir plus Sofosbuvir versus Sofosbuvir plus Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-Adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Noviello, Stephanie
    Signorovitch, James
    HEPATOLOGY, 2015, 62 : 561A - 561A
  • [5] Daclatasvir plus asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison
    Swallow, Elyse
    Kelley, Caroline
    Signorovitch, James
    Wygant, Gail
    McPhee, Fiona
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (03) : 273 - 279
  • [6] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [7] Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC
    Castro, Elena
    Wang, Di
    Walsh, Sarah
    Craigie, Samantha
    Haltner, Anja
    Nazari, Jonathan
    Niyazov, Alexander
    Samjoo, Imtiaz A.
    FUTURE ONCOLOGY, 2025,
  • [8] Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Loomis, Timothy P.
    Mole, Larry A.
    Backus, Lisa I.
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 15 - 23
  • [9] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
  • [10] Personalised prophylaxis with simoctocog alfa versus standard emicizumab prophylaxis in haemophilia A, a matching-adjusted indirect comparison
    Kessler, C. M.
    Corrales-Medina, F. F.
    MannuccioMannucci, P.
    Astermark, J.
    Tarantino, M. D.
    HAEMOPHILIA, 2024, 30 : 55 - 55
12345